Filtered By:
Condition: Hemorrhagic Stroke
Drug: Warfarin

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 721 results found since Jan 2013.

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research

Successful use of therapeutic anticoagulation therapy in two patients with moderate stroke from the second day of onset: A case report and literature review
CONCLUSION: As a result of this case report, clinical improvement has not been associated with hemorrhagic sequelae of anticoagulant administration on the first day. At this point, we recommend conducting a trial to study the effect of early application of anticoagulants from the first day on clinical outcome, recurrence, and hemorrhagic transfusion of stroke.PMID:36268411 | PMC:PMC9577847 | DOI:10.1016/j.amsu.2022.104726
Source: Annals of Medicine - October 21, 2022 Category: Internal Medicine Authors: Mostafa Meshref Nour Shaheen Rehab Adel Diab Mariam Tarek Desouki Yara Amro Shiamaa M Khairat Mohamed Ali Mahmoud Galal Ahmed Source Type: research

Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
Conclusions Among patients with nonvalvular AFib, apixaban was as effective as rivaroxaban in reducing rate of stroke and safer in terms of major bleeding episodes. This head-to-head comparison supports conclusions drawn from indirect comparisons of DOAC trials against warfarin and demonstrates the potential for real-world evidence to fill evidence gaps and reduce uncertainty in both health technology assessment decision-making and clinical guideline development.
Source: BMJ Open - October 17, 2022 Category: General Medicine Authors: Jaksa, A., Gibbs, L., Kent, S., Rowark, S., Duffield, S., Sharma, M., Kincaid, L., Ali, A. K., Patrick, A. R., Govil, P., Jonsson, P., Gatto, N. Tags: Open access, Cardiovascular medicine Source Type: research

Long-term outcome and risk factors associated with events in patients with atrial fibrillation treated with oral anticoagulants: The ASSAF-K registry
CONCLUSIONS: This multi-center registry demonstrated the long-term outcome in patients with AF treated with and without OACs and suggests that DOAC therapy is safe and beneficial in hospitals and clinics.PMID:36109256 | DOI:10.1016/j.jjcc.2022.08.012
Source: Journal of Cardiology - September 15, 2022 Category: Cardiology Authors: Yutaka Hatori Hiroyuki Sakai Nobuo Hatori Tomoyuki Kunishima Atsuo Namiki Makoto Shimizu Nobuo Toyosaki Masaomi Kuwajima Naoki Sato ASSAF-K investigators Source Type: research

Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research

Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
ConclusionsIn this real-world study of NVAF patients with obesity, rivaroxaban was associated with lower risks of stroke and systemic embolism and similar risk of major bleeding versus warfarin across polypharmacy categories.
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research

Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin for Treating Left Ventricular Thrombus
ConclusionsIn this diverse population-based cohort of patients, DOAC treatment for left ventricular thrombus appears to be as safe and effective as warfarin treatment. These findings support the use of DOACs for patients with left ventricular thrombus.
Source: American Journal of Cardiovascular Drugs - July 1, 2022 Category: Cardiology Source Type: research

Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
ConclusionBased on this analysis, rivaroxaban seemed to be a better option in comparison to warfarin, due to its association with significantly lower risks of stroke and bleeding outcomes in obese patients with non-valvular AF. However, this hypothesis should further be confirmed in larger clinical trials.
Source: Cardiovascular Drugs and Therapy - June 28, 2022 Category: Cardiology Source Type: research

Po-713-05 ischemic stroke after prophylaxis with left atrial appendage closure vs non-warfarin oral anticoagulants: a “real-world” multicenter comparison of stroke severity
In randomized trials, strokes occurring in patients who have received left atrial appendage closure (LAAC) devices have been less severe than in patients receiving warfarin prophylaxis - an observation thought related to warfarin ’s higher rate of hemorrhagic stroke (which are known to have worse outcomes). Similar stroke rates have been described with LAAC vs NOACs (non-warfarin oral anticoagulants), but the low hemorrhagic stroke rate of NOACs raises the question of stroke severity between these two therapies.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Mohit K. Turagam, Iwanari Kawamura, Domenico G. Della Rocca, Pavel Hala, Thomas Flautt, Deji Adedokun, Moritoshi Funasako, Daniel Ross Musikantow, Srinivas R. Dukkipati, David H. Yoo, Petr Neuzil, Devi G. Nair, Douglas N. Gibson, Miguel Valderrabano, Andr Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: a Systematic Review and Meta-analysis
ConclusionDOACs were associated with better efficacy and safety profiles than warfarin in atrial fibrillation patients with prior stroke, more specifically a lower risk of systemic embolism, all-cause mortality, and ICH.
Source: Cardiovascular Drugs and Therapy - April 25, 2022 Category: Cardiology Source Type: research

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
CONCLUSIONS: Low-dose NOACs were comparable to standard-dose NOACs considering risks of ischemic stroke, major bleeding, ICH, and GH, and they were superior to warfarin. Low-dose NOACs might be prescribed effectively and safely for patients with AF. Considering limitations, further well-designed prospective studies are foreseen.PMID:35449605 | PMC:PMC9017587 | DOI:10.1155/2022/4713826
Source: Cardiology Research and Practice - April 22, 2022 Category: Cardiology Authors: Ze Li Xiaozhen Wang Dandan Li Aiping Wen Source Type: research